Thread by @HCC_HemeCancer

🧵🧵
1/18
We at HCC are so proud of our team and participating centers. 6 abstracts of our collective work have been accepted for #ASH22. If you wish to be a part of this movement either as an individual or as a participating institution, do visit us at hemecancer.org/membership.php

@chepsyphilip @pb10_bmt @udaypkulkarni @NancyArthurPhD @DrArunCMC @dranupjdevasia @DrNikitaMehra @faheema_hasan @madhavi_maddali @jayastuMD @MJosephJohn1 @dbhurani @lingarajnayak @Prasshmehta @hkJain_kmc @b_poonkuzhali @nvpatkar @rayaz_hemat @drmanuprasad

2/18
#2976 Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemia from a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
ash.confex.com/ash/2022/webpr…

3/18
➡️Analysis of clinical characteristics, treatment patterns, outcomes, and prognostic factors in adolescent and adult newly diagnosed BL diagnosed between 2012-2019 (including HIV positive) from 8 participating member institutions

4/18
➡️🩺Treatment of adolescent and adult Burkitt lymphoma and leukemia with intensive regimens (high-dose methotrexate-based) and dose-adjusted EPOCH regimen comparable.
➡️Dose-adjusted EPOCH-based regimen - preferred in older patients.
➡️Addition of 💊rituximab 📈improves OS

#ASH22
5/18
#1407 Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
ash.confex.com/ash/2022/webpr…
➡️2013-2018 to evaluate the outcomes in all risk groups (as per Sanz score), mortality within first 30-days and prognostic factors.

6/18
➡️Low/intermediate risk were treated with ATRA and ATO-based therapy whereas the high-risk group received chemotherapy in addition to ATRA/ATO.
➡️No statistically significant difference between low, intermediate, and high-risk groups for any of the survival outcomes.

7/18
➡️Baseline WBC of >40000/cumm and serum creatinine of >2 mg/dL at diagnosis adversely affected the overall survival

#ASH22
8/18
#1397 Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
ash.confex.com/ash/2022/webpr…

9/18
➡️Prospective data for adult AML, for a period of 20 months, wef July'20-Feb'22, received from 17 member institutions.
➡️Predictive model using machine learning (ML) algorithms: Logistic regression (LR), Support Vector Machine (SVM) and eXtreme Gradient Boosting (XGB).

10/18
➡️The SVM model predicted the risk of both induction mortality as well as morbidity with high accuracy

#ASH22
11/18
#3022 Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
ash.confex.com/ash/2022/webpr…

12/18
➡️First multicenter investigator-initiated clinical trial from India on Chronic myeloid Leukemia-9 participating centrs➡️CCyR of 89.7% in patients who have completed 12 months of therapy

13/18
➡️At interim analysis Dasatinib 50 mg appears promising with respect to responses but with a caution - majority of patients had a higher disease load.

#ASH22
14/18
#2716 Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
ash.confex.com/ash/2022/webpr…
➡️17 participating centers in India

15/18
➡️Patients older than 55 years diagnosed between January 2018 and April 2021.
➡️Complete remission (CR) was achieved in 24(36%) patients after intensive chemotherapy.

16/18
➡️Low rates of treatment initiation and significant treatment discontinuation within one year in patients older than 55 years of age with AML in India.
➡️Financial challenges emerge as major modifiable factors leading to incomplete treatment.

#ASH22
17/18
#3628 Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
ash.confex.com/ash/2022/webpr…
➡️Comparison of the pre-COVID pandemic period with outcomes for AML during the pandemic in India from 17 participating member institutions

18/18
➡️Outcomes for patients who received treatment for AML during the COVID pandemic were comparable with the pre-COVID period
➡️Continuing standard of care even during the pandemic is feasible and intensive induction with a transplant can be offered even during the pandemic.

🛑End of tweet

#hematology #clinicalresearch #collaborativeresearch #realworldevidence #oncology #patientadvocacy #lymsm #mmsm #bloodcancer #PatientCare #leusm #MedEd #leusm #CLL #MedTwitter
#qualityoflife #QoL